Scarica l'app Stockscreener
24.79
0.41%
0.10
Dopo l'orario di chiusura:
24.78
-0.010
-0.04%
Precedente Chiudi:
$24.69
Aprire:
$25.25
Volume 24 ore:
705.77K
Relative Volume:
0.98
Capitalizzazione di mercato:
$975.44M
Reddito:
$734.86M
Utile/perdita netta:
$5.14M
Rapporto P/E:
198.32
EPS:
0.125
Flusso di cassa netto:
$132.71M
1 W Prestazione:
-2.44%
1M Prestazione:
+9.21%
6M Prestazione:
+13.46%
1 anno Prestazione:
-3.95%
Intervallo 1D:
$24.74
$25.60
Intervallo di 1 settimana:
$23.47
$27.13
Portata 52W:
$18.80
$27.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, TEVA, HLN, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
24.79 | 971.50M | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-11-17 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-25 | Aggiornamento | Truist | Hold → Buy |
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Pacira BioSciences Mails Letter to Stockholders - The Manila Times
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety - ChartMill
How Pacira’s Q1 2026 Results, EXPAREL Data and Proxy Battle May Impact Pacira BioSciences (PCRX) Investors - Sahm
Price-Driven Insight from (PCRX) for Rule-Based Strategy - Stock Traders Daily
Assessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World Data - Yahoo Finance
Pacira Biosciences Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Sales Forecast Maintained - Moomoo
Universal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences (PCRX) Return To Profitability Tests Bullish Growth Narratives - Sahm
Pacira BioSciences Reports Strong First Quarter Growth for EXPAREL - HarianBasis.co
MSN Money - MSN
PCRX Maintained by RBC Capital -- Price Target Raised to $24 - GuruFocus
PCRX Maintained by Needham -- Price Target Raised to $32 - GuruFocus
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y - The Globe and Mail
Royal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price - MarketBeat
Pacira BioSciences Stock (US6951271005): Analyst Rating Change and Price Move on May 1, 2026 - AD HOC NEWS
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst Upgrade - MarketBeat
RBC Raises Price Target on Pacira Biosciences to $24 From $22, Keeps Sector Perform Rating - marketscreener.com
Vanguard Capital Management (PCRX) reports 2.09M-share stake in Pacira - Stock Titan
Vanguard Portfolio Management (PCRX) reports 2.59M shares, 6.38% stake - Stock Titan
Pacira (PCRX) Q1 2026 Earnings Call Transcript - AOL.com
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release - Yahoo Finance
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2026 Earnings Call Transcript - Insider Monkey
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release - The Motley Fool
Pacira BioSciences Inc (PCRX) Q1 2026 Earnings Call Highlights: Strong Product Growth Amidst Challenges - GuruFocus
Pacira outlines 2026 revenue guidance of $745M-$770M while advancing PCRX-201 Phase II milestones - MSN
Pacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Pacira BioSciences Q1 2026 Earnings Call Transcript - MarketBeat
Pacira BioSciences Q1 Earnings Call Highlights - MarketBeat
Pacira BioSciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-04-30 - Seeking Alpha
Pacira BioSciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Pacira BioSciences : Corporate Sustainability Report (pacira corporate sustainability report 2024 v1 20260430) - marketscreener.com
Is Pacira BioSciences (PCRX) Undervalued After Q1 2026? GAAP EPS - GuruFocus
PCRX Sets Ambitious Goals for FY26 with Strong Clinical Focus - GuruFocus
Do options traders know something about Pacira BioSciences stock we don't? - MSN
Pacira BioSciences (PCRX) Reports Strong Q1 Revenue Growth - GuruFocus
Pacira Biosciences (NASDAQ:PCRX) Q1 2026 Results Beat Estimates as Key Pipeline Catalysts Near - ChartMill
Q1 2026 Pacira Biosciences Inc Earnings Call Transcript - GuruFocus
Earnings Flash (PCRX) Pacira BioSciences, Inc. Posts Q1 Adjusted EPS $0.60 per Share, vs. FactSet Est of $0.55 - marketscreener.com
Earnings Flash (PCRX) Pacira BioSciences, Inc. Reports Q1 Revenue $177.4M, vs. FactSet Est of $171.8M - marketscreener.com
Pacira BioSciences (NASDAQ: PCRX) Q1 2026 revenue reaches $177M - Stock Titan
Pacira BioSciences (NASDAQ: PCRX) grows Q1 revenue 5% and reaffirms 2026 guidance - Stock Titan
Pacira BioSciences 1Q EPS 7c >PCRX - Moomoo
MSN - MSN
symbol__ Stock Quote Price and Forecast - CNN
Pacira BioSciences Inc. (PCRX) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders - The Manila Times
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 - 富途牛牛
Is It Too Late to Buy Pacira BioSciences Inc (PCRX) After 4.3% R - GuruFocus
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.67%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):